Financings in Brief: I-Flow
This article was originally published in The Gray Sheet
I-Flow: Irvine, California-based company announces plans to lower the exercise price and extend the expiration date for its publicly held warrants that were set to expire on June 30, 1995. The warrants may now be redeemed at an exercise price of $2.25 per share (down from $3.81) until July 31, 1995...
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.